ProCE Banner Activity

Managing Low- and High-Risk Myelodysplastic Syndromes: Experts Address FAQs

Clinical Thought
In this commentary, 3 expert faculty answer audience questions from a live satellite symposium presented at ASCO 2022 on the management of myelodysplastic syndromes.

Released: August 09, 2022

Expiration: August 08, 2023

Share

Faculty

Amy E. DeZern

Amy E. DeZern, MD, MHS

Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Rami S. Komrokji

Rami S. Komrokji, MD

Professor of Oncologic Sciences
Department of Oncologic Sciences
University of Florida
Senior Member/Clinical Director
Malignant Hematology
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Amer Zeidan

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Bristol Myers Squibb

Karyopharm Therapeutics Inc.

Program Director Disclosure

Program Director

Rami S. Komrokji, MD

Professor of Oncologic Sciences
Department of Oncologic Sciences
University of Florida
Senior Member/Clinical Director
Malignant Hematology
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Rami S. Komrokji, MD: consultant: AbbVie, Acceleron, Agios/Servier, Bristol-Myers Squibb/Celgene, Geron, Jazz, Novartis, PharmaEssentia, Taiho.

Faculty Disclosure

Primary Author

Amy E. DeZern, MD, MHS

Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Amy E. DeZern, MD, MHS: consultant: Bristol-Myers Squibb, CTI BioPharma, Geron, Novartis, Taiho.

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Amer Zeidan, MBBS, MHS: consultant: AbbVie, Acceleron, Agios, Amgen, Aprea, Astellas, BeyondSpring, Boehringer Ingelheim, Cardiff Oncology, Celgene/Bristol-Myers Squibb, Daiichi Sankyo, Epizyme, Geron, Gilead Sciences, Incyte, Ionis, Janssen, Jazz, Kura, Novartis, Otsuka, Pfizer, Seattle Genetics, Syndax, Taiho, Takeda, Trovagene, Tyme; researcher: AbbVie, ADC Therapeutics, Amgen, Aprea, Astex, Boehringer Ingelheim, Cardiff Oncology, Celgene/Bristol-Myers Squibb, Incyte, Medimmune/AstraZeneca, Novartis, Otsuka, Pfizer, Takeda, Trovagene.